Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.60 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | DRD4 | P21917 | 8/20 | 0.47 |
| ▸ | DRD3 | P35462 | 8/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496463 | 0.77 | CRBN (0.62) | CRBNDRD2SIGMAR1ALDH1A1 | |
| SCHEMBL21496470 | 0.75 | CRBN (1.00) | CRBN | |
| SCHEMBL22932163 | 0.74 | DRD3 (0.50) | CRBNDRD2DRD4DRD3HTR1A | |
| SCHEMBL1750627 | 0.69 | SIGMAR1 (0.58) | DRD2DRD4DRD3SIGMAR1HTR1A | |
| SCHEMBL22018722 | 0.69 | CRBN (0.49) | CRBN | |
| SCHEMBL22932066 | 0.68 | CRBN (0.50) | CRBN | |
| SCHEMBL28262836 | 0.67 | ALDH1A1 (0.57) | DRD2DRD4DRD3SIGMAR1HTR1A | |
| SCHEMBL19586513 | 0.67 | CRBN (0.55) | CRBNALDH1A1 | |
| SCHEMBL22932089 | 0.66 | CRBN (0.51) | CRBN | |
| SCHEMBL13772456 | 0.66 | SIGMAR1 (0.58) | DRD2DRD4DRD3SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885DRD2 4192/4885DRD4 3894/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CRBN 1/4885DRD2 4192/4885DRD4 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.